Skip to main content
Top
Published in:

09-05-2024 | Cholangiocarcinoma | Adis Drug Evaluation

Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma

Author: Sheridan M. Hoy

Published in: Targeted Oncology | Issue 3/2024

Login to get access

Abstract

Futibatinib (LYTGOBI®) is an oral small molecule compound that selectively, irreversibly and potently inhibits the tyrosine kinase activity of fibroblast growth factor receptor (FGFR)1–4. It is approved in the EU, Japan and the USA for the treatment of adults with locally advanced or metastatic cholangiocarcinoma (CCA) harbouring an FGFR2 fusion or rearrangement who have progressed following systemic therapy. In the phase II part (FOENIX-CCA2) of a multinational phase I/II study in this patient population, monotherapy with futibatinib 20 mg once daily was associated with clinically meaningful and durable responses, sustained health-related quality of life (HR-QOL), and a manageable safety profile with supportive care and as-needed dose modifications. Indeed, hyperphosphataemia (the most common all grade and grade 3 treatment-related adverse event) was manageable with phosphate-lowering therapy and dose reductions or interruptions. Although further efficacy and tolerability data are expected, current evidence indicates that futibatinib is a valuable targeted therapy option for adults with locally advanced or metastatic CCA harbouring an FGFR2 fusion or rearrangement who have progressed following systemic therapy, a patient population with limited treatment options and poor life expectancy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127–40.CrossRefPubMed Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127–40.CrossRefPubMed
2.
go back to reference National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: biliary tract cancers. Version 3.2023 – November 8, 2023. 2023. https://www.nccn.org/. Accessed 19 Feb 2024. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: biliary tract cancers. Version 3.2023 – November 8, 2023. 2023. https://​www.​nccn.​org/​. Accessed 19 Feb 2024.
3.
go back to reference Rushbrook SM, Kendall TJ, Zen Y, et al. British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut. 2023;73(1):16–46.CrossRefPubMed Rushbrook SM, Kendall TJ, Zen Y, et al. British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut. 2023;73(1):16–46.CrossRefPubMed
4.
go back to reference Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–88.CrossRefPubMedPubMedCentral Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–88.CrossRefPubMedPubMedCentral
6.
go back to reference Javle M, King G, Spencer K, et al. Futibatinib, an irreversible FGFR1-4 inhibitor for the treatment of FGFR-aberrant tumors. Oncologist. 2023;28(11):928–43.CrossRefPubMedPubMedCentral Javle M, King G, Spencer K, et al. Futibatinib, an irreversible FGFR1-4 inhibitor for the treatment of FGFR-aberrant tumors. Oncologist. 2023;28(11):928–43.CrossRefPubMedPubMedCentral
7.
go back to reference Wekking D, Pretta A, Martella S, et al. Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas. Heliyon. 2023;9(9): e19541.CrossRefPubMedPubMedCentral Wekking D, Pretta A, Martella S, et al. Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas. Heliyon. 2023;9(9): e19541.CrossRefPubMedPubMedCentral
11.
go back to reference Kalyukina M, Yosaatmadja Y, Middleditch MJ, et al. TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem. 2019;14(4):494–500.CrossRefPubMed Kalyukina M, Yosaatmadja Y, Middleditch MJ, et al. TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem. 2019;14(4):494–500.CrossRefPubMed
12.
go back to reference Sootome H, Fujita H, Ito K, et al. Futibatinib is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80(22):4986–97.CrossRefPubMed Sootome H, Fujita H, Ito K, et al. Futibatinib is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80(22):4986–97.CrossRefPubMed
13.
go back to reference Valery M, Vasseur D, Fachinetti F, et al. Targetable molecular alterations in the treatment of biliary tract cancers: an overview of the available treatments. Cancers (Basel). 2023;15(18):4446.CrossRefPubMed Valery M, Vasseur D, Fachinetti F, et al. Targetable molecular alterations in the treatment of biliary tract cancers: an overview of the available treatments. Cancers (Basel). 2023;15(18):4446.CrossRefPubMed
14.
go back to reference Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9(8):1064–79.CrossRefPubMedPubMedCentral Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9(8):1064–79.CrossRefPubMedPubMedCentral
15.
go back to reference Cleary JM, Raghavan S, Wu Q, et al. FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma. Cancer Discov. 2021;11(10):2488–505.CrossRefPubMedPubMedCentral Cleary JM, Raghavan S, Wu Q, et al. FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma. Cancer Discov. 2021;11(10):2488–505.CrossRefPubMedPubMedCentral
16.
go back to reference Bahleda R, Meric-Bernstam F, Goyal L, et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol. 2020;31(10):1405–12.CrossRefPubMed Bahleda R, Meric-Bernstam F, Goyal L, et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol. 2020;31(10):1405–12.CrossRefPubMed
17.
go back to reference Hollebecque A, Bridgewater JA, Meric-Bernstam F, et al. Assessment of futibatinib exposure-response (E-R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA) [abstract no. 52P]. Ann Oncol. 2021;32(Suppl 5):S378–9.CrossRef Hollebecque A, Bridgewater JA, Meric-Bernstam F, et al. Assessment of futibatinib exposure-response (E-R) relationships in patients with advanced solid tumors, including cholangiocarcinoma (CCA) [abstract no. 52P]. Ann Oncol. 2021;32(Suppl 5):S378–9.CrossRef
18.
go back to reference Yamamiya I, Lester R, Sonnichsen D, et al. Effect of futibatinib on cardiac repolarization: results of a randomized, controlled, double-blind, QT/QTc, phase 1 study in healthy subjects. Clin Pharmacol Drug Dev. 2023;12(3):304–13.CrossRefPubMed Yamamiya I, Lester R, Sonnichsen D, et al. Effect of futibatinib on cardiac repolarization: results of a randomized, controlled, double-blind, QT/QTc, phase 1 study in healthy subjects. Clin Pharmacol Drug Dev. 2023;12(3):304–13.CrossRefPubMed
19.
go back to reference Yamamiya I, Hunt A, Yamashita F, et al. Evaluation of potential food effects and drug interactions with lansoprazole in healthy adult volunteers receiving futibatinib. Clin Pharmacol Drug Dev. 2023;12(3):294–303.CrossRefPubMed Yamamiya I, Hunt A, Yamashita F, et al. Evaluation of potential food effects and drug interactions with lansoprazole in healthy adult volunteers receiving futibatinib. Clin Pharmacol Drug Dev. 2023;12(3):294–303.CrossRefPubMed
20.
go back to reference Yamamiya I, Hunt A, Takenaka T, et al. Evaluation of the cytochrome P450 3A and p-glycoprotein drug-drug interaction potential of futibatinib. Clin Pharmacol Drug Dev. 2023;12(10):966–78.CrossRefPubMed Yamamiya I, Hunt A, Takenaka T, et al. Evaluation of the cytochrome P450 3A and p-glycoprotein drug-drug interaction potential of futibatinib. Clin Pharmacol Drug Dev. 2023;12(10):966–78.CrossRefPubMed
21.
go back to reference Gao L, Yamamiya I, Pinti M, et al. A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib. Clin Transl Sci. 2023;16(9):1713–24.CrossRefPubMedPubMedCentral Gao L, Yamamiya I, Pinti M, et al. A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib. Clin Transl Sci. 2023;16(9):1713–24.CrossRefPubMedPubMedCentral
22.
go back to reference Doi T, Shitara K, Kojima T, et al. Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors. Cancer Sci. 2023;114(2):574–85.CrossRefPubMed Doi T, Shitara K, Kojima T, et al. Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors. Cancer Sci. 2023;114(2):574–85.CrossRefPubMed
23.
go back to reference Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228–39.CrossRefPubMed Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228–39.CrossRefPubMed
24.
go back to reference Bridgewater J, Meric-Bernstam F, Hollebecque A, et al. Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: subgroup analyses of a phase II study (FOENIX-CCA2) [abstract no. 54P]. Ann Oncol. 2020;31(Suppl 4):S261–2.CrossRef Bridgewater J, Meric-Bernstam F, Hollebecque A, et al. Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: subgroup analyses of a phase II study (FOENIX-CCA2) [abstract no. 54P]. Ann Oncol. 2020;31(Suppl 4):S261–2.CrossRef
27.
go back to reference Goyal L, Meric-Bernstam F, Hollebecque A, et al. Updated results of the FOENIX-CCA2 trial: efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements [abstract no. 4009]. J Clin Oncol. 2022;40(16 Suppl). Goyal L, Meric-Bernstam F, Hollebecque A, et al. Updated results of the FOENIX-CCA2 trial: efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements [abstract no. 4009]. J Clin Oncol. 2022;40(16 Suppl).
28.
go back to reference Borad MJ, Paine A, Wacheck V, et al. Indirect treatment comparison of futibatinib with chemotherapy and pemigatinib in cholangiocarcinoma with FGFR2 fusions/rearrangements [abstract no. 440]. J Clin Oncol. 2022;40(4 Suppl):400. Borad MJ, Paine A, Wacheck V, et al. Indirect treatment comparison of futibatinib with chemotherapy and pemigatinib in cholangiocarcinoma with FGFR2 fusions/rearrangements [abstract no. 440]. J Clin Oncol. 2022;40(4 Suppl):400.
Metadata
Title
Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma
Author
Sheridan M. Hoy
Publication date
09-05-2024
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 3/2024
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-024-01059-8

Other articles of this Issue 3/2024

Targeted Oncology 3/2024 Go to the issue